Peak Bio Common Stock Net 2021-2024 | PKBO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Peak Bio common stock net from 2021 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Peak Bio common stock net from 2021 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$180.5B
Regeneron Pharmaceuticals (REGN)	$126.8B
Vertex Pharmaceuticals (VRTX)	$123.3B
Gilead Sciences (GILD)	$104.5B
Bristol Myers Squibb (BMY)	$99.4B
CSL (CSLLY)	$97.5B
GSK (GSK)	$86.3B
Alnylam Pharmaceuticals (ALNY)	$35.5B
Argenex SE (ARGX)	$32.1B
Biogen (BIIB)	$29.3B
BioNTech SE (BNTX)	$26.8B
Moderna (MRNA)	$26.1B
Illumina (ILMN)	$21.4B
BeiGene (BGNE)	$19.3B
Genmab (GMAB)	$17.5B
BioMarin Pharmaceutical (BMRN)	$13.6B
Exact Sciences (EXAS)	$13.1B
Vaxcyte (PCVX)	$13.1B
Insmed (INSM)	$12.9B
Incyte (INCY)	$12.9B
Bio-Techne Corp (TECH)	$12.7B
Sarepta Therapeutics (SRPT)	$12.1B
QIAGEN (QGEN)	$10.4B
Legend Biotech (LEGN)	$9.3B
Bio-Rad Laboratories (BIO.B)	$9.1B
Ascendis Pharma (ASND)	$8.9B
Roivant Sciences (ROIV)	$8.8B
Repligen (RGEN)	$8.2B
Intra-Cellular Therapies (ITCI)	$8.1B
Exelixis (EXEL)	$7.7B